Boston Scientific Corporation
BSX
Classificação em ações
#409
Esta descrição da empresa está disponível apenas em inglês.
Boston Scientific Corporation (BSX) operates as a global leader in medical... Boston Scientific Corporation (BSX) operates as a global leader in medical technology, specializing in the design, manufacturing, and commercialization of innovative medical devices tailored for a diverse array of interventional medical specialties across the globe. Its business is strategically organized into three principal segments: MedSurg, Rhythm and Neuro, and Cardiovascular. Within these divisions, the company provides a comprehensive portfolio of solutions addressing various gastrointestinal and pulmonary ailments, as well as urological and pelvic health concerns. This extends to advanced implantable devices for managing cardiac rhythm disorders, such as cardioverter-defibrillators, cardiac resynchronization therapy devices, and pacemakers, complemented by remote patient management systems. Furthermore, Boston Scientific offers sophisticated technologies for diagnosing and treating complex heart rate and rhythm irregularities. These encompass 3-D cardiac mapping and navigation tools, along with a suite of specialized catheters (including ablation, diagnostic, mapping, and intracardiac ultrasound types), delivery sheaths, and related accessories. Its offerings also extend to neurological conditions, providing spinal cord stimulator systems for chronic pain management, indirect decompression systems, and deep brain stimulation systems. In the realm of interventional cardiology, the company's innovations include drug-eluting coronary stent systems designed for treating coronary artery disease, products for percutaneous coronary interventions to combat atherosclerosis, and intravascular imaging catheters (such as ultrasound and fractional flow reserve devices) for assessing coronary arteries, heart chambers, and peripheral vessels. It also develops structural heart therapies. Beyond this, Boston Scientific supplies an array of stents, balloon catheters, wires, and atherectomy systems for the treatment of arterial diseases. For venous conditions, it provides thrombectomy and acoustic pulse thrombolysis systems, alongside wires and stents. Critically, the company also contributes to cancer treatment through peripheral embolization devices, radioactive microspheres, various ablation systems (including cryotherapy), and micro and drainage catheters. The organization was established in 1979 and maintains its corporate headquarters in Marlborough, Massachusetts.
Preço da ação
$41.88
Última sincronização: 2026-10-30
Valor de mercado
$60.69B
Variação (1 dia)
-1.89%
Variação (1 ano)
-58.42%
País
US
Dados de ações: Financial Modeling Prep·Atualizado em ·Não é aconselhamento de investimento·Como calculamos
Negociar Boston Scientific Corporation (BSX)
Categoria
Healthcare
Lucros da Boston Scientific Corporation (BSX)
Lucros em Sep 2026 TTM: $3.66B
De acordo com os últimos relatórios financeiros da Boston Scientific Corporation, os ganhos atuais da empresa são de $3.66B. Em 2025, a empresa teve ganhos de $3.39B, um aumento em relação a aos ganhos de 2024, que foram de $2.28B. Os ganhos apresentados nesta página são os ganhos antes de juros e impostos, conhecidos como EBIT.
Histórico de lucros da Boston Scientific Corporation de 2000 a 2026
Lucros no final de cada ano
| Ano | Lucros | Variação |
|---|---|---|
| 2026 (TTM) | $3.66B | 7.98% |
| 2025 | $3.39B | 48.33% |
| 2024 | $2.28B | 14.96% |
| 2023 | $1.99B | 73.97% |
| 2022 | $1.14B | 6.04% |
| 2021 | $1.08B | -1,462.03% |
| 2020 | $-79.00M | -111.50% |
| 2019 | $687.00M | -51.69% |
| 2018 | $1.42B | 52.41% |
| 2017 | $933.00M | 427.12% |
| 2016 | $177.00M | -127.23% |
| 2015 | $-650.00M | 27.70% |
| 2014 | $-509.00M | 128.25% |
| 2013 | $-223.00M | -94.57% |
| 2012 | $-4.11B | -739.72% |
| 2011 | $642.00M | -160.40% |
| 2010 | $-1.06B | -18.73% |
| 2009 | $-1.31B | -35.60% |
| 2008 | $-2.03B | 256.94% |
| 2007 | $-569.00M | -83.90% |
| 2006 | $-3.54B | -496.75% |
| 2005 | $891.00M | -40.36% |
| 2004 | $1.49B | 132.35% |
| 2003 | $643.00M | 17.12% |
| 2002 | $549.00M | 1,147.73% |
| 2001 | $44.00M | -91.65% |
| 2000 | $527.00M | 0.00% |
Lucros de empresas semelhantes ou concorrentes
| Empresa | Lucros | Diferença de Lucros | País |
|---|---|---|---|
| $6.56B | 79.53% |
US
|
|
| $6.60B | 80.66% |
IE
|
|
| $5.12B | 39.97% |
US
|
|
| $3.23B | -11.70% |
DE
|
|
| $1.42B | -61.21% |
US
|
Perguntas sobre o lucro líquido de Boston Scientific Corporation
Qual é o lucro líquido de Boston Scientific Corporation?
Segundo os dados mais recentes (set 2026), o lucro líquido de Boston Scientific Corporation nos últimos doze meses é de $3.66B.
Qual foi o lucro líquido de Boston Scientific Corporation em 2025?
Em 2025, o lucro líquido de Boston Scientific Corporation foi de $3.39B, um aumento de 48.33% em relação a 2024 ($2.28B).
Como evoluiu o lucro líquido de Boston Scientific Corporation desde 2020?
De 2020 a 2025, o lucro líquido de Boston Scientific Corporation atingiu o valor mais alto em 2025 ($3.39B) e o mais baixo em 2020 ($-79.00M).
Como se compara o lucro líquido de Boston Scientific Corporation com empresas semelhantes?
Com $3.66B, o lucro líquido de Boston Scientific Corporation supera o valor de 2 das 5 empresas semelhantes listadas acima. Entre elas, o valor mais alto é o de Medtronic plc ($6.60B).